Toxicity of phosphate enemas - an updated review
Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbanc...
Saved in:
Published in | Clinical toxicology (Philadelphia, Pa.) Vol. 60; no. 6; pp. 672 - 680 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
03.06.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1556-3650 1556-9519 1556-9519 |
DOI | 10.1080/15563650.2022.2054424 |
Cover
Abstract | Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.
To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.
A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.
The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.
Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken. |
---|---|
AbstractList | Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.
To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.
A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.
The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.
Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken. Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.INTRODUCTIONEnemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.OBJECTIVESTo review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.METHODSA systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.RESULTSThe searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.CONCLUSIONPhosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken. |
Author | Hamilton Smith, Rosa Bateman, D. Nicholas Eddleston, Michael |
Author_xml | – sequence: 1 givenname: Rosa surname: Hamilton Smith fullname: Hamilton Smith, Rosa organization: Stirling High School – sequence: 2 givenname: Michael orcidid: 0000-0002-6857-3441 surname: Eddleston fullname: Eddleston, Michael organization: National Poisons Information Service - Edinburgh, Royal Infirmary of Edinburgh – sequence: 3 givenname: D. Nicholas orcidid: 0000-0002-8971-862X surname: Bateman fullname: Bateman, D. Nicholas organization: Pharmacology, Toxicology & Therapeutics, Centre for Cardiovascular Science, University of Edinburgh |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35510830$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkMlOwzAURS1URAf4BFCWbFI8JrHYgComqRKbsracxFGNEjvYCaV_j6OmLFjAxsPTuVd6Zw4mxhoFwCWCSwQzeIMYS0jC4BJDjMPBKMX0BMyGecwZ4pPxPUBTMPf-HUKSUY7OwJQwFkoInAG4sV-60N0-slXUbq1vt7JTkTKqkT6KI2mivi3DqIyc-tRqdw5OK1l7dTHeC_D2-LBZPcfr16eX1f06LigiXSxpqfI8RYgrwrIyoyh8CSVSpixTKUoZLROWpJBTDHPMCiYrnnHIMQyMqsgCXB96W2c_euU70WhfqLqWRtneC5wkEEGUJllAr0a0zxtVitbpRrq9OG4ZAHYACme9d6r6QRAUg01xtCkGm2K0GXK3v3LBlOy0NZ2Tuv43fXdIa1NZ18iddXUpOrmvraucNIX2gvxd8Q2A8YpW |
CitedBy_id | crossref_primary_10_3390_children11030349 crossref_primary_10_53126_MEB43649 |
Cites_doi | 10.1016/j.jconrel.2015.04.040 10.1177/000992280504400114 10.2147/IJGM.S44417 10.1055/s-0035-1548839 10.1093/qjmed/hcx165 10.1007/s10620-005-2780-9 10.1016/j.curtheres.2006.10.004 10.3238/arztebl.2015.0781 10.1007/s00467-010-1570-6 10.4067/S0370-41062017000300011 10.1042/CS20100377 10.1007/s00414-009-0344-9 10.1002/14651858.CD000330.pub3 10.2169/internalmedicine.47.0704 10.1097/PEC.0b013e31823b0088 10.5414/CN110345 10.1016/j.jemermed.2019.07.009 10.1111/jgs.13588 10.1007/s00383-012-3124-4 10.1001/archinternmed.2011.694 10.1007/s00431-009-0999-8 10.1111/ans.16360 10.1007/s00431-008-0705-2 10.1097/SGA.0b013e3181e26ec2 10.1373/clinchem.2011.170183 10.1111/j.1365-2036.2007.03354.x 10.1053/j.ajkd.2015.11.018 10.1097/PEC.0000000000000267 |
ContentType | Journal Article |
Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022 |
Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022 |
DBID | 0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1080/15563650.2022.2054424 |
DatabaseName | Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1556-9519 |
EndPage | 680 |
ExternalDocumentID | 35510830 10_1080_15563650_2022_2054424 2054424 |
Genre | Review Systematic Review Journal Article |
GroupedDBID | --- 00X 03L 0BK 0R~ 0YH 29B 36B 4.4 5RE AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABXYU ACENM ACGFS ACIEZ ACUHS ADCVX ADRBQ AECIN AENEX AEOZL AFKVX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC BABNJ BLEHA BOHLJ CCCUG DKSSO DU5 EAP EAS EBC EBD EBS EDH EHN EMB EMK EMOBN EPL EPT ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- Q~Q RNANH RVRKI SV3 TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UHWXJ V1S ~1N AAGDL AAYXX ABWVI ADYSH AFRVT AMPGV CITATION .GJ 34G 39C 3O- 53G 5VS AALIY ABCRQ ACKYO AGAFX AJEBJ AWYRJ CAG CGR COF CUY CVF DEIEU DTRLO DZHFC ECM EIF EJD LSO M44 NPM NUSFT QRXOQ 7X8 TASJS |
ID | FETCH-LOGICAL-c413t-a4debb7119e358d841ebb343aa758e71754d656709420b25c5af98909203aaef3 |
IEDL.DBID | 0YH |
ISSN | 1556-3650 1556-9519 |
IngestDate | Sun Aug 24 03:46:52 EDT 2025 Wed Feb 19 02:26:02 EST 2025 Tue Jul 01 03:38:12 EDT 2025 Thu Apr 24 22:50:24 EDT 2025 Wed Dec 25 09:07:11 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | toxicity enemas Phosphate hyperphosphataemia |
Language | English |
License | open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c413t-a4debb7119e358d841ebb343aa758e71754d656709420b25c5af98909203aaef3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-6857-3441 0000-0002-8971-862X |
OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/15563650.2022.2054424 |
PMID | 35510830 |
PQID | 2660101768 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmed_primary_35510830 proquest_miscellaneous_2660101768 informaworld_taylorfrancis_310_1080_15563650_2022_2054424 crossref_citationtrail_10_1080_15563650_2022_2054424 crossref_primary_10_1080_15563650_2022_2054424 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-06-03 |
PublicationDateYYYYMMDD | 2022-06-03 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Clinical toxicology (Philadelphia, Pa.) |
PublicationTitleAlternate | Clin Toxicol (Phila) |
PublicationYear | 2022 |
Publisher | Taylor & Francis |
Publisher_xml | – name: Taylor & Francis |
References | Muller-Lissner SA (CIT0003) 2010; 07 CIT0030 CIT0010 Marek I (CIT0014) 2015; 227 CIT0032 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 Núñez Sánchez MJ (CIT0015) 2017; 88 CIT0013 Carl I (CIT0018) 2007; 76 CIT0035 CIT0016 Yu M (CIT0009) 2015; 167 CIT0017 Caswell M. (CIT0025) 2009; 107 CIT0021 CIT0020 CIT0001 CIT0023 CIT0022 Kosseifi S (CIT0019) 2008; 106 CIT0002 CIT0024 CIT0005 CIT0027 CIT0004 CIT0026 CIT0007 CIT0029 CIT0006 CIT0028 CIT0008 |
References_xml | – ident: CIT0001 doi: 10.1016/j.jconrel.2015.04.040 – ident: CIT0017 doi: 10.1177/000992280504400114 – volume: 07 start-page: 1 year: 2010 ident: CIT0003 publication-title: BMJ Clin Evid – ident: CIT0032 doi: 10.2147/IJGM.S44417 – volume: 227 start-page: 235 year: 2015 ident: CIT0014 publication-title: Klin Padiatr doi: 10.1055/s-0035-1548839 – ident: CIT0034 doi: 10.1093/qjmed/hcx165 – ident: CIT0006 – volume: 107 start-page: 28 issue: 1 year: 2009 ident: CIT0025 publication-title: J Ky Med Assoc – ident: CIT0027 doi: 10.1007/s10620-005-2780-9 – ident: CIT0029 doi: 10.1016/j.curtheres.2006.10.004 – ident: CIT0035 doi: 10.3238/arztebl.2015.0781 – ident: CIT0016 doi: 10.1007/s00467-010-1570-6 – volume: 88 start-page: 383 issue: 3 year: 2017 ident: CIT0015 publication-title: Rev Chil Pediatr doi: 10.4067/S0370-41062017000300011 – ident: CIT0002 doi: 10.1042/CS20100377 – ident: CIT0010 doi: 10.1007/s00414-009-0344-9 – ident: CIT0004 doi: 10.1002/14651858.CD000330.pub3 – ident: CIT0022 doi: 10.2169/internalmedicine.47.0704 – ident: CIT0031 doi: 10.1097/PEC.0b013e31823b0088 – volume: 106 start-page: 431 issue: 9 year: 2008 ident: CIT0019 publication-title: J Ky Med Assoc – ident: CIT0023 doi: 10.5414/CN110345 – ident: CIT0026 doi: 10.1016/j.jemermed.2019.07.009 – ident: CIT0028 doi: 10.1111/jgs.13588 – ident: CIT0012 doi: 10.1007/s00383-012-3124-4 – volume: 167 start-page: 237 year: 2015 ident: CIT0009 publication-title: J Louisiana State Med Soc – ident: CIT0020 doi: 10.1001/archinternmed.2011.694 – ident: CIT0024 doi: 10.1007/s00431-009-0999-8 – ident: CIT0008 doi: 10.1111/ans.16360 – ident: CIT0011 doi: 10.1007/s00431-008-0705-2 – ident: CIT0030 doi: 10.1097/SGA.0b013e3181e26ec2 – ident: CIT0005 – ident: CIT0021 doi: 10.1373/clinchem.2011.170183 – ident: CIT0007 doi: 10.1111/j.1365-2036.2007.03354.x – ident: CIT0033 doi: 10.1053/j.ajkd.2015.11.018 – ident: CIT0013 doi: 10.1097/PEC.0000000000000267 – volume: 76 start-page: 172 year: 2007 ident: CIT0018 publication-title: Ulster Med J |
SSID | ssj0038491 |
Score | 2.3590899 |
SecondaryResourceType | review_article |
Snippet | Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the... |
SourceID | proquest pubmed crossref informaworld |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 672 |
SubjectTerms | Aged Calcium Child Child, Preschool Enema - adverse effects enemas Hirschsprung Disease - chemically induced Humans hyperphosphataemia Hypotension - chemically induced Laxatives - toxicity Phosphate Phosphates - toxicity toxicity |
Title | Toxicity of phosphate enemas - an updated review |
URI | https://www.tandfonline.com/doi/abs/10.1080/15563650.2022.2054424 https://www.ncbi.nlm.nih.gov/pubmed/35510830 https://www.proquest.com/docview/2660101768 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA-6vQgifjs_RgRfo22TbOnjpo4h6NMG-hTSJmGCtsV24J_vpWmHPow9-FjIpe1dc_e79O4XhG5MZFOIwiHhQ8MJMyIgiasiBMcXBzrhWtRVlc8vg-mcPb3ytpqwbMoqXQ5tPVFE7avd4lZJ2VbE3YWO1AqQBWR3keul4oxFbBt1IwCKrqoveJu2zpgKFnvKVD4gTqZt4lk3zZ_w9Ie8dD0ErUPRZB_tNRgSj7zRD9CWyQ7Rrt-Aw76v6AgFs_z7PQWMjXOLi0VeFguAlRhc26cqMcEqw8vCpfsa-_aVYzSfPM7up6Q5HoGkEHkqopg2STIMw9hQLrRgIVxSRpWCHMBAmsaZBrQ2hAQuCpKIp1zZWIANogDGGEtPUCfLM3OGsFJc65rNTKQsTm0MA4U14Ckh4QkN7SHWakWmDXe4O8LiQ4YNxWirTOmUKRtl9tDtSqzw5BmbBOLfKpdVvWth_REjkm6QvW7tI2GJuP8eKjP5spSAQRyTHrxMD516w60eB-AWTEmD83_c-QLtuMu6gIxeok71tTRXAFWqpF9_jH3UHY0fxpMfpVfZUw |
linkProvider | Taylor & Francis |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA86Dwoifjs_I3iNtk2ypUcRR9Vtpw3mKaRtwgRti-vAP9-Xph3bQXbwWJqXtu8lL7-XvvcLQnc6MAmswj7hXc0J08Ijsc0iBMcXemnMU1FlVQ6GnWjMXid8slQLY9MqbQxtHFFE5avt5Lab0U1K3INvWa0AWkB4F9hiKs5YwDbRFhcQTcCY9t6jxhtTwULHmco7xMo0VTx_dbOyPq2wl_6NQau1qLeP9moQiR-d1Q_Qhs4O0a7bgcOusOgIeaP85yMBkI1zg4tpPiumgCsx-LYvNcMEqwzPCxvvp9jVrxyjce959BSR-nwEksDSUxLFUh3HXd8PNeUiFcyHS8qoUhAEaIjTOEsBrnUhggu8OOAJVyYUYITAgzba0BPUyvJMnyGsFE_Tis5MJCxMTAgNhdHgKiHi8TVtI9ZoRSY1ebg9w-JT-jXHaKNMaZUpa2W20f1CrHDsGesEwmWVy7LatjDujBFJ18jeNvaRMEfsjw-V6Xw-kwBCLJUefEwbnTrDLV4H8BZ0Sb3zfzz5Bm1Ho0Ff9l-Gbxdox96qssnoJWqV33N9BbiljK-rgfkLoLTbTA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA86QQQRv52fEXyttk2yJY-ijvk1fNhAn0LaJEzQttgN_PO9NO3Qh7EHH0t7aXvX3P0uvfsFoQsT2xSicBSwrmEBNTwMEldFCI5PhDphmldVlc-DTn9EH15ZU01Y1mWVLoe2niii8tVuchfaNhVxV5EjtQJkAdld7HqpGKUxXUYrjIsKI4Vv_cYZE06Fp0xlncDJNE0884b5E57-kJfOh6BVKOptoo0aQ-Jrb_QttGSybbTuF-Cw7yvaQeEw_35PAWPj3OJinJfFGGAlBtf2qUocYJXhaeHSfY19-8ouGvXuhjf9oN4eIUgh8kwCRbVJkm4UCUMY15xGcEgoUQpyAANpGqMa0FoXErg4TGKWMmUFBxvEIVxjLNlDrSzPzAHCSjGtKzYznlKRWgEXcmvAU0LCExnSRrTRikxr7nC3hcWHjGqK0UaZ0ilT1spso8uZWOHJMxYJiN8ql5Nq1cL6LUYkWSB73thHwhRx_z1UZvJpKQGDOCY9eJk22veGmz0OwC0YkoSH_7jzGVp9ue3Jp_vB4xFac2eqWjJyjFqTr6k5AdQySU6r7_IHUa_adQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toxicity+of+phosphate+enemas+-+an+updated+review&rft.jtitle=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.au=Hamilton+Smith%2C+Rosa&rft.au=Eddleston%2C+Michael&rft.au=Bateman%2C+D.+Nicholas&rft.date=2022-06-03&rft.pub=Taylor+%26+Francis&rft.issn=1556-3650&rft.eissn=1556-9519&rft.volume=60&rft.issue=6&rft.spage=672&rft.epage=680&rft_id=info:doi/10.1080%2F15563650.2022.2054424&rft.externalDBID=0YH&rft.externalDocID=2054424 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-3650&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-3650&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-3650&client=summon |